• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15922 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2010 The Regional Health Technology Assessment Centre (HTA-centrum) 90Yttrium radioembolisation for hepatocellular carcinoma and colorectal liver metastases
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Early identification of sepsis: a review of the evidence for clinical indicators and guidelines for management
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Epidermal growth factor receptor mutation analysis in advanced non-small cell lung cancer: review of economic evaluations and framework for economic analyses
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Hyperbaric oxygen therapy for difficult wound healing: systematic review of clinical effectiveness and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Self-directed cognitive behavioural therapy for adults with diagnosis of depression: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cannabinoids for the management of neuropathic pain: review of clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Use of diuretics for hypertension in patients with reduced renal function: a review of clinical effectiveness, safety, and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Telepathology: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Methods to screen for hemoglobin S in blood donors selected for exchange transfusions: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Optimizing the implementation of diagnostic imaging decision support tools: a review of the evidence and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cannabinoids as co-analgesics: review of clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Negative pressure therapy for patients infected wounds: a review of the clinical and cost-effectiveness evidence and recommendations for use
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Silver dressings for the treatment of patients with infected wounds: a review of clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Patient lifts and transfer equipment: a review of clinical and cost-effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Chair alarms in residential care and acute care: a review of the clinical effectiveness and safety
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Deep brain stimulation for parkinson's disease and neurological movement disorders: a review of the clinical and cost-effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of periodontal disease in patients with diabetes: a review of clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Drug therapy for prophylactic and post-exposure treatment of H1N1: a review of the comparative clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Lindane and other treatments for lice and scabies: a review of clinical effectiveness and safety
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography for epilepsy: clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Bluetooth-enabled hearing technologies: a review of the clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Varenicline for smoking cessation in patients with psychiatric illness: a review of the risks
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Pain scales in acute care settings: a review of the accuracy and reliability
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Prefabricated and custom made foot orthotics: a review of the clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Infliximab for maintenance therapy for treatment of Crohn's disease: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Percutaneous heart valves for valvular heart disease: an updated review of the clinical and cost-effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Albumin versus synthetic plasma volume expanders: a review of the clinical and cost-effectiveness and guidelines for use
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve implantation: a critical appraisal of a health technology assessment and comparison with a rapid review
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cognitive behavioural therapy for insomnia in adults: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Remote ischemic conditioning: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Screening programs for asymptomatic unruptured intracranial aneurysms: review of clinical effectiveness, cost-effectiveness, and evidence-based guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Positive versus negative needleless connectors for central venous lines and peripheral lines: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Use of bupropion in patients with depression and the associated risk of seizures: safety
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Eden alternative and green house concept of care: review of clinical effectiveness, cost-effectiveness, and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Bifocal lenses under +0.50 diopter: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Pre-operative screening and post-operative monitoring in adult patients with obstructive sleep apnea: clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Sternal talon for cardiac surgery patients: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Tinnitus retraining therapy: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Pre-hospital phlebotomy for patients with urgent conditions: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Laser refractive surgery in children: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Laparoscopic sleeve gastrectomy: a review of the clinical benefits and harms
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Filtered needles for withdrawing medication from glass ampoules: a review of the cost-effectiveness and incidence of complications
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Periodontal regenerative procedures for patients with periodontal disease: a review of clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Completely-in-the-canal and bone anchored hearing aids: a review of the clinical effectiveness and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Critical incident stress debriefing for first responders: a review of the clinical benefit and harm
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cognitive behavioural therapy for patients with addictions: a review of the clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Atypical antipsychotics for the treatment of schizophrenia: a review of combination therapy and high-dosing strategies
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Tramadol compared with opioids for pain: a review of addiction potential
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Percutaneous heart valve replacement for valvular heart disease: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cognitive behavioural therapy for post traumatic stress disorder: a review of the clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for non-hodgkin's lymphoma: a review of the clinical and cost- effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Use of antipsychotics and/or benzodiazepines as rapid tranquilization in inpatients of mental facilities and emergency departments: a review of the clinical effectiveness and guidelines
2010 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [10th Symposium Health Technology Assessment, Nothing without evidence? 18th-19th March 2010, Cologne]
2010 Andalusian Health Technology Assessment Area (AETSA) [Serum biomarkers panel for detecting early stage ovarian cancer]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Standards for appropriate use of health technologies. Total hip arthroplasty]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and economic assessment of the percutaneous aortic valve implantation]
2010 Andalusian Health Technology Assessment Area (AETSA) [Oxygen carriers. Production of red blood cells from human embryonic stem cells]
2010 Andalusian Health Technology Assessment Area (AETSA) [Gene expression test for breast cancer Oncotype]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in acute abdominal pain]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Cardiac resynchronization therapy. Economic evaluation]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessments reports : assessment of ethical issues in health technologies assessment]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery in colorectal cancer : quality of life, psychological impact and patient satisfaction]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in primary and secondary care : ultrasonography in breast pathology]
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography (PET) in oncology: a systematic review of clinical effectiveness and indications for use
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Percutaneuos transcatheter closure of patent foramen ovale]
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Specialist nurse-led clinic]
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Transcatheter aortic valve prosthesis implantation (TAVI)]
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic peritoneal lavage for patients with perforated diverticulitis]
2010 Technology Assessment Unit of the McGill University Health Centre (MUHC) Argon beam coagulation in orthopaedic, urological and thoracic surgery at the MUHC: a brief report
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ranolazine (Ranexa®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Atazanavir (Reyataz®) capsules
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Sildenafil citrate (Revatio®) solution
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) capsules
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) oral solution
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Epoetin theta (Eporatio®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Olanzapine depot (ZypAdhera)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Cetuximab (Erbitux®) for third-line treatment of patients with KRAS wild-type metastatic colorectal cancer
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Epoetin alfa (Binocrit®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (TevaGrastim®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (Zarzio®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Sildenafil (Revatio®) for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretrovirals for the treatment of HIV-1 infection in adults
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pramipexole prolonged release tablets (Mirapexin®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Epoetin zeta (Retacrit®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Fentanyl (Instanyl®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Enoxaparin (Clexane®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paclitaxel albumin (Abraxane®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Bortezomib (Velcade®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Plerixafor (Mozobil®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Etanercept (Enbrel®)
2010 Institute of Health Economics (IHE) Evidence on the effectiveness of telerehabilitation applications
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic response modifier agents for adults with rheumatoid arthritis
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and a sulfonylurea
2010 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Use of telemedicine between Rigshospitalet and Bornholm Hospital: report of a pilot project]